Last reviewed · How we verify
NCT05432492
A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Completed
Phase 2
Last updated 4 March 2026
What this trial tests
Phase 2 trial testing AK112 in Hepatocellular Carcinoma in 40 participants. Completed in 14 June 2025.
Timeline
3 August 2022
Primary endpoint
30 April 2025
30 April 2025
14 June 2025
Quick facts
| Lead sponsor | Akeso |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 3 August 2022 |
| Primary completion | 30 April 2025 |
| Estimated completion | 14 June 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- AK112 — full drug profile →
Conditions studied
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Sponsor
Akeso — full company profile →
Who can join
Adults 18 to 75, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Phase II open label, multicenter study to evaluate the efficacy and safety of AK112 (PD-1/VEGF Bispecific) in patients with unresectable hepatocellular carcinoma (HCC).
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy.
Zhang T, Lin Y, Gao Q. · · 2023 · cited 47× · PMID 36971124 · DOI 10.20892/j.issn.2095-3941.2023.0002 -
Immune Checkpoint Inhibitor Combined with Antiangiogenic Agent Synergistically Improving the Treatment Efficacy for Solid Tumors.
Zhou Y, Liu Z, Yu A, Zhao G, et al · · 2024 · cited 17× · PMID 39763508 · DOI 10.2147/itt.s494670 -
Unlocking new horizons in oncology: ivonescimab's dual-target approach to anti-VEGF/PD-1(L1) therapy.
Shi F, Yang L, Gao Y, Hou Y, et al · · 2025 · cited 4× · PMID 41333457 · DOI 10.3389/fimmu.2025.1599181 -
Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma.
Koh B, Tan DJH, Lim WH, Wong JSL, et al · · 2023 · cited 4× · PMID 37284696 · DOI 10.1080/2162402x.2023.2214478
Verify or expand the search:
- PubMed search for NCT05432492
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of AK112
Trials testing the same drug.
- NCT07357220 — A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases · Phase 1, PHASE2 · not yet recruiting
- NCT07385001 — A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as N · Phase 1, PHASE2 · recruiting
- NCT07021950 — AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07052253 — A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. · Phase 2 · recruiting
- NCT07010263 — A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progress · Phase 3 · recruiting
Other recruiting trials for Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
- NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
- NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting
Other Akeso trials
Trials by the same sponsor.
- NCT07449780 — A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XEL · Phase 3 · not yet recruiting
- NCT07412613 — Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer · Phase 3 · not yet recruiting
- NCT07357220 — A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases · Phase 1, PHASE2 · not yet recruiting
- NCT07436234 — A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis · Phase 2 · not yet recruiting
- NCT07436221 — A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT05432492 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Akeso
- Last refreshed: 4 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05432492.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing